Results 151 to 160 of about 2,379 (179)

Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis

Pediatric Pulmonology, 2021
Ashlee Anderson, Lindsey McCoy, Rebecca S. Pettit, Brittany A. Wright, Lisa Lubsch   +4 more
openaire   +2 more sources

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2022
Sarah Jane Schwarzenberg, Scott Sagel, David Nichols   +2 more
exaly  

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

American Journal of Respiratory and Critical Care Medicine, 2021
Samuel Moskowitz, Mcnally P, Bonnie Ramsey   +2 more
exaly  

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

Journal of Cystic Fibrosis, 2022
Max Petersen
exaly  

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Mirjam Stahl, Felix C Ringshausen, Simon Y Graeber   +2 more
exaly  

Elexacaftor‐tezacaftor‐ivacaftor overdose in an adolescent female with cystic fibrosis

Pediatric Pulmonology, 2022
Benjamin C. Lyman, Jessica Seay, Casey Contreary, Adrienne P. Savant, Mary Lynn Dell, George C. Hescock   +5 more
openaire   +2 more sources

Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series

Journal of Cystic Fibrosis, 2022
Andrea Gramegna, Francesco Blasi, Roberto Meazza   +2 more
exaly  

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine, 2022
Samuel Moskowitz, Alexander Moeller, Paul Robinson   +2 more
exaly  

Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method

Biomedicines, 2023
Francesca Mattioli, Sebastiano Barco, Federico Cresta   +2 more
exaly  

Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal
Peter G. Middleton, Nicholas J. Simmonds
openaire   +2 more sources